Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Revenue (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Revenue for 3 consecutive years, with $1.3 million as the latest value for Q2 2025.

  • On a quarterly basis, Revenue rose 1200.0% to $1.3 million in Q2 2025 year-over-year; TTM through Sep 2025 was -$1.3 million, a 79.85% increase, with the full-year FY2024 number at $200000.0, down 88.89% from a year prior.
  • Revenue was $1.3 million for Q2 2025 at Inhibrx Biosciences, up from -$2.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.6 million in Q4 2023 to a low of -$8.1 million in Q3 2023.
  • A 3-year average of -$2.0 million and a median of $65000.0 in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: tumbled 93.88% in 2024, then surged 1200.0% in 2025.
  • Inhibrx Biosciences' Revenue stood at $1.6 million in 2023, then crashed by 93.88% to $100000.0 in 2024, then soared by 1200.0% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Revenue are $1.3 million (Q2 2025), -$2.7 million (Q1 2025), and $100000.0 (Q4 2024).